04/22/2002
By Harvey McConnell
An eight year follow-up of pravastatin treatment has shown sustained treatment benefits and safety for patients with previous acute coronary syndromes and average cholesterol concentrations.
These findings reinforce the importance of long-term cholesterol-lowering treatment for almost all patients with previous coronary heart disease events, declares lead author Dr John Simes of the Clinical Trials Center, University of Sydney, Sydney, Australia.
The recommendation is based on the original Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study, a randomised placebo-controlled trial undertaken at 87 centers in Australia and New Zealand. The study involved 9,014 patients who had had an acute myocardial infarction, or a hospital discharge diagnosis of unstable angina pectoris three to 36 months before study entry, and whose total cholesterol concentration was 4.0-7.0 mmol/L.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!